NASDAQ: RPRXRoyalty Pharma PLC Stock Ownership - Who owns Royalty Pharma?
Insider buying vs selling
Have Royalty Pharma PLC insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Henry A. Fernandez | Director | 2025-06-30 | 1,064 | $35.24 | $37.49kBuy |
| Bonnie L. Bassler | Director | 2025-06-30 | 1,064 | $35.24 | $37.49kBuy |
| Henry A. Fernandez | Director | 2025-03-31 | 1,141 | $32.87 | $37.50kBuy |
| Bonnie L. Bassler | Director | 2025-03-31 | 1,141 | $32.87 | $37.50kBuy |
| Bonnie L. Bassler | Director | 2024-12-31 | 1,503 | $24.94 | $37.49kBuy |
| Henry A. Fernandez | Director | 2024-12-31 | 1,503 | $24.94 | $37.49kBuy |
| Henry A. Fernandez | Director | 2024-09-30 | 1,342 | $27.93 | $37.48kBuy |
| Bonnie L. Bassler | Director | 2024-09-30 | 1,342 | $27.93 | $37.48kBuy |
RPRX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when RPRX insiders and whales buy or sell their stock.
RPRX Shareholders
What type of owners hold Royalty Pharma PLC stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Morgan Stanley | 7.30% | 41,029,832 | $1.47B | Institution |
| Fmr LLC | 7.01% | 39,404,093 | $1.41B | Institution |
| Adage Capital Partners GP LLC | 6.89% | 38,714,280 | $1.39B | Insider |
| Vanguard Group Inc | 6.52% | 36,677,448 | $1.32B | Institution |
| Blackrock Inc | 4.37% | 24,555,862 | $880.82M | Institution |
| 1978 Sicaf Sif Sa 1. Gg | 3.93% | 22,081,156 | $792.05M | Insider |
| 1978 Sicaf Sif Sa Gg | 3.81% | 21,426,170 | $768.56M | Insider |
| Baillie Gifford Co | 2.38% | 13,402,284 | $480.74M | Institution |
| Swedbank Ab | 2.16% | 12,157,470 | $436.09M | Institution |
| Viking Global Investors LP | 1.88% | 10,563,939 | $378.93M | Institution |
RPRX vs Biotech Stocks
Royalty Pharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.